The US Food & Drug Administration’s new cell and gene therapy operation is falling a bit short on its ambitious hiring goals, but the head of the Center for Biologics Evaluation & Research is accentuating the positive during a key year for the new organization.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?